Featured Research

from universities, journals, and other organizations

Pepper Compound Could Aid Millions With Vitiligo

Date:
April 15, 2008
Source:
Oregon Health & Science University
Summary:
A family of compounds derived from black pepper extract have shown potential in animal studies to be effective in treating vitiligo, a skin pigmentation disorder. Vitiligo, which afflicts an estimated 100 million people worldwide, is characterized by the loss of pigment in affected areas of skin.

Oregon Health & Science University has licensed a family of compounds derived from black pepper extract – on which it owns the patents – to AdPharma, Inc. for potential pharmaceutical development. The compounds have shown potential in animal studies to be effective in treating vitiligo, a skin pigmentation disorder.

Vitiligo, which afflicts an estimated 100 million people worldwide, is characterized by the loss of pigment in affected areas of skin. It is the disease pop star Michael Jackson has publicly disclosed that he has. It is neither life-threatening nor contagious. But the sometimes unsightly white patches it causes produce emotional distress for many and often lead to social ostracism because of a widespread misperception that the condition is infectious.

An estimated 1 percent to 2 percent of the world’s population suffers from the malady. Current treatments, which rely on immunosuppression or ultraviolet radiation to stimulate repigmentation, are only partially effective, often producing a mottled appearance. Excessive ultraviolet (UV) radiation also poses the risk of skin cancer.

“Based on the animal studies we have done, these compounds, if proved safe in humans, promise far superior results in the treatment of vitiligo than current approaches,” said Amala Soumyanath, Ph.D., an associate professor of neurology, OHSU School of Medicine. “Vitiligo is a highly visible disease that can greatly affect patients psychologically and emotionally, even driving some to consider suicide. Any breakthrough in treating it would benefit a huge number of people around the world.”

Soumyanath and her collaborators reported on the effects of their compounds in animals in a paper just published in the British Journal of Dermatology. But development of the concept dates back more than a decade. Soumyanath discovered – in research on vitiligo that she initiated at King’s College London – that piperine, the alkaloid in black pepper responsible for its pungency, stimulated the proliferation of melanocytes in cell cultures. Melanocytes are the cells that produce pigmentation in the skin. The researchers then designed and tested many synthetic piperine analogs and identified a number that produced the same result.

The group subsequently found that piperine and two of its analogs – tetrahydropiperine (THP) and a cyclohexyl derivative (RCHP) produced light, even pigmentation when applied to the skin of a poorly pigmented mouse model. When combined with UV radiation, the skin grew significantly darker and showed none of the patchiness caused by UV treatment alone. Moreover, skin pre-treated with a piperine compound required fewer UV exposures, thus lowering the cancer risk, and it took longer for the pigmentation to fade again than when UV alone was used.

Since coming to OHSU in 2002, Soumyanath has established new collaborations with scientific and clinical researchers to continue work on this project. “Dr. Soumyanath’s recent discoveries open up completely new and exciting treatment possibilities for those individuals affected by vitiligo,” said Andrew Blauvelt, M.D., professor of dermatology at OHSU and one of Soumyanath’s recent collaborators. “There is a huge unmet need for this disease because we have very few treatments to offer patients right now,” he noted.

OHSU acquired the patents to Soumyanath’s piperine compounds from King’s College London and BTG International Ltd. in 2006 and succeeded in finding a commercial partner, AdPharma, to advance the compounds through pharmaceutical development. Soumyanath has a financial interest in AdPharma. This potential conflict has been disclosed to the OHSU Conflict of Interest in Research committee for management.

AdPharma, a diverse pharmaceutical company headquartered in Arlington Heights, Ill., licenses promising compounds from scientists, universities and biotech companies and advances them through the clinical testing stage. “Our key strength is being able to identify, through our computer models and past experience, promising drugs which we can then drive through our strong development structure,” said Anil Sunkara, the company’s chief executive officer.

The next step before clinical trials can be undertaken, said Soumyanath, is to determine in animal models whether the repigmentation effects of piperine compounds is associated in any way with melanoma or other skin cancers. “From our mouse studies so far, it doesn’t appear that is the case,” she said, “and we are hopeful that more detailed research will bear this out. OHSU has ideal facilities and expertise for further preclinical and clinical studies, and we are excited to have the support of AdPharma as we move toward testing these compounds in human vitiligo.”


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "Pepper Compound Could Aid Millions With Vitiligo." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080413172937.htm>.
Oregon Health & Science University. (2008, April 15). Pepper Compound Could Aid Millions With Vitiligo. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/04/080413172937.htm
Oregon Health & Science University. "Pepper Compound Could Aid Millions With Vitiligo." ScienceDaily. www.sciencedaily.com/releases/2008/04/080413172937.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins